Michael Barbella, Managing Editor07.10.23
Insulet Corporation has announced a new organizational structure designed to accelerate innovation and commercialization. The new structure is being implemented during the second half of this year with new leadership roles effective July 1, 2023. The leadership team will continue to report to President/CEO Jim Hollingshead.
“It is an exciting time at Insulet as we continue to advance our mission to improve the lives of people with diabetes. Our company has achieved remarkable growth, recently accelerated by the U.S. commercial launch of our Omnipod 5 Automated Insulin Delivery System," Hollingshead said. "The global markets and customers we serve have also rapidly evolved. Now is the ideal time to realign our organizational structure to support our strong momentum, accelerate our innovation pipeline, and drive continued global expansion. Our new organizational design creates a more focused and specialized structure that strengthens our commercial capabilities and fosters further innovation and cross-functional collaboration.”
As part of the new organizational structure, the following roles have been created:
Field has more than 20 years of experience building and leading high-performing software engineering teams that develop complex, connected systems, and most recently served as group vice president, Software Engineering, overseeing Insulet’s Mobile and Cloud software teams since 2019. Prior to joining Insulet, Field was chief technology officer at Thermo Fisher Scientific, among other roles, where he led a global team responsible for Thermo Fisher’s IoT connected device programs, cloud-based scientific services, and E-commerce. Before joining Thermo Fisher, Field was an executive at Oracle Corporation. He has degrees in computer science and business from the University of Auckland in New Zealand.
The previous chief commercial officer role has been separated into two positions in order to drive more focused regional and local market execution. In connection with the internal reorganization, Executive Vice President/Chief Commercial Officer Bret Christensen left the company to pursue other opportunities.
“Bret has played an integral role in the commercial successes of the company over the last six years, most recently with the U.S. commercial launch of Omnipod 5 and the continued global expansion of Omnipod DASH,” Hollingshead stated. “He helped build a deep, talented commercial team that has contributed to our strong customer base growth, an exceptional customer experience, and differentiated business model and pharmacy channel access. All of us at Insulet wish Bret well in his next endeavor.”
The company has begun searching for a general manager who will focus on accelerating U.S. commercial growth, go-to-market strategies, and sales operations. This newly created role will also drive enhanced and consistent global commercial capabilities across the enterprise.
International General Manager Patrick Crannell will continue to oversee the company’s international commercial operations. He is responsible for leading go-to-market execution and expansion in international markets, as well as the strategic, commercial, operational, and financial performance of the international operations. Crannell will now report directly to Hollingshead.
Crannell has vast experience managing operations internationally having spent 10 years living and working in Europe and the Middle East. Through various general manager and commercial roles, he has served as Insulet’s senior vice president, head of International, since August 2022. Before joining Insulet, Crannell was vice president of Infusion Therapy and Medical Devices at ICU Medical, where he led a large U.S. team and drove record growth through implementation of a new commercial model and aligned incentives across three different business units. Prior to that, he was vice president, general manager, of ICU’s Infusion Consumables Business Unit, which operated in more than 60 countries, with direct affiliate and distributor teams. Before joining ICU Medical, he was vice president, International, at Pfizer in London and previously served as vice president for Hospira (later acquired by Pfizer), overseeing the U.K., Ireland, Benelux, and Compounding businesses. Crannell earned an MBA with a concentration in management from the University of St. Thomas in St. Paul, Minn.
“Consumer-focused innovation is central to everything we do. As our business becomes larger and more complex, we have structured our operations and leadership to more efficiently and effectively drive and scale our innovations and support our commercial and operational priorities," Hollingshead said. "With the changes, Insulet is better positioned to continue driving customer adoption, international expansion, and enhanced customer experience as we support hundreds of thousands of people with diabetes across the globe.”
Headquartered in Massachusetts, Insulet Corporation is dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible smartphone or Omnipod 5 Controller. Insulet also leverages the design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
“It is an exciting time at Insulet as we continue to advance our mission to improve the lives of people with diabetes. Our company has achieved remarkable growth, recently accelerated by the U.S. commercial launch of our Omnipod 5 Automated Insulin Delivery System," Hollingshead said. "The global markets and customers we serve have also rapidly evolved. Now is the ideal time to realign our organizational structure to support our strong momentum, accelerate our innovation pipeline, and drive continued global expansion. Our new organizational design creates a more focused and specialized structure that strengthens our commercial capabilities and fosters further innovation and cross-functional collaboration.”
As part of the new organizational structure, the following roles have been created:
- Eric Benjamin has been named chief Product & Customer Experience Officer (CPXO), responsible for product vision and execution, including franchise management and global growth strategies, product and portfolio management, and driving the end-to-end customer experience across the enterprise.
- Mark Field has been named chief Technology Officer, responsible for software and hardware engineering, information technology, cyber security, digital and data services, and system architecture. Field is responsible for ensuringthe company continues to have robust software platforms, modules, and other technology capabilities to support Insulet’s strategy and goals.
Field has more than 20 years of experience building and leading high-performing software engineering teams that develop complex, connected systems, and most recently served as group vice president, Software Engineering, overseeing Insulet’s Mobile and Cloud software teams since 2019. Prior to joining Insulet, Field was chief technology officer at Thermo Fisher Scientific, among other roles, where he led a global team responsible for Thermo Fisher’s IoT connected device programs, cloud-based scientific services, and E-commerce. Before joining Thermo Fisher, Field was an executive at Oracle Corporation. He has degrees in computer science and business from the University of Auckland in New Zealand.
The previous chief commercial officer role has been separated into two positions in order to drive more focused regional and local market execution. In connection with the internal reorganization, Executive Vice President/Chief Commercial Officer Bret Christensen left the company to pursue other opportunities.
“Bret has played an integral role in the commercial successes of the company over the last six years, most recently with the U.S. commercial launch of Omnipod 5 and the continued global expansion of Omnipod DASH,” Hollingshead stated. “He helped build a deep, talented commercial team that has contributed to our strong customer base growth, an exceptional customer experience, and differentiated business model and pharmacy channel access. All of us at Insulet wish Bret well in his next endeavor.”
The company has begun searching for a general manager who will focus on accelerating U.S. commercial growth, go-to-market strategies, and sales operations. This newly created role will also drive enhanced and consistent global commercial capabilities across the enterprise.
International General Manager Patrick Crannell will continue to oversee the company’s international commercial operations. He is responsible for leading go-to-market execution and expansion in international markets, as well as the strategic, commercial, operational, and financial performance of the international operations. Crannell will now report directly to Hollingshead.
Crannell has vast experience managing operations internationally having spent 10 years living and working in Europe and the Middle East. Through various general manager and commercial roles, he has served as Insulet’s senior vice president, head of International, since August 2022. Before joining Insulet, Crannell was vice president of Infusion Therapy and Medical Devices at ICU Medical, where he led a large U.S. team and drove record growth through implementation of a new commercial model and aligned incentives across three different business units. Prior to that, he was vice president, general manager, of ICU’s Infusion Consumables Business Unit, which operated in more than 60 countries, with direct affiliate and distributor teams. Before joining ICU Medical, he was vice president, International, at Pfizer in London and previously served as vice president for Hospira (later acquired by Pfizer), overseeing the U.K., Ireland, Benelux, and Compounding businesses. Crannell earned an MBA with a concentration in management from the University of St. Thomas in St. Paul, Minn.
“Consumer-focused innovation is central to everything we do. As our business becomes larger and more complex, we have structured our operations and leadership to more efficiently and effectively drive and scale our innovations and support our commercial and operational priorities," Hollingshead said. "With the changes, Insulet is better positioned to continue driving customer adoption, international expansion, and enhanced customer experience as we support hundreds of thousands of people with diabetes across the globe.”
Headquartered in Massachusetts, Insulet Corporation is dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible smartphone or Omnipod 5 Controller. Insulet also leverages the design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.